Stockwinners Market Radar for June 17, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT VS Media Holdings Ltd trading halted, news pending

19:50 EDT Forward Industries trading halted, news pending

18:00 EDT Astronics awarded $215M contract from U.S. Army - Astronics announced it has been awarded the production contract for the U.S. Army Radio Test Set TS-4549/T. The award provides for the program management, engineering, and product manufacturing to support the operational readiness of the Army's extensive range of radio communication devices. The firm-fixed price, indefinite delivery, indefinite quantity contract has a total value of up to $215M with an expected period of performance of five years. The contract was awarded with an initial delivery order of $15.5M to cover qualification and low-rate initial production. The company expects this effort will generate revenue of approximately $10M-$12M in 2024 of which $5M-$7M is expected in the second quarter.

17:32 EDT FDA approves Merck's CAPVAXIVE in IPD cases - The company states: "Merck announced that the FDA has approved CAPVAXIVE, Pneumococcal 21-valent Conjugate Vaccine, for: Active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older; Active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older. CAPVAXIVE is specifically designed to help protect adults against the serotypes that cause the majority of invasive pneumococcal disease, or IPD, cases. The approval follows the FDA's Priority Review of Merck's application. This indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of CAPVAXIVE in adults. These values are based on CDC epidemiologic data and do not reflect the efficacy of the respective vaccines. There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20. CAPVAXIVE includes eight unique serotypes not covered by other currently approved pneumococcal vaccines; those serotypes were responsible for approximately 27% of IPD cases in adults 50 years of age and older and approximately 30% in adults 65 years of age and older, based on the same CDC data."

17:06 EDT Pan American Silver provides mid-year exploration update - The company states: "Pan American Silver releases new drill results for its Jacobina, El Penon, La Colorada and Huaron properties, reflecting the potential for continued mineral resource replacement at these assets. In particular, drill results from La Colorada and El Penon reveal the significant exploration potential to find additional mineralized structures in under-explored ground surrounding these operations, highlighting the potential for mineral resource growth close to existing mine infrastructure. Pan American's exploration program focuses on near-mine exploration and mineral resource conversion throughout its portfolio. Since the last exploration update provided on December 5, 2023, a total of 223,157 metres have been drilled over the November 1, 2023 to April 30, 2024 period. The Company plans to drill an additional 200,000 metres from May 2024 to December 2024."

16:43 EDT Dynatrace CEO McConnell sells 50,000 common shares - In a regulatory filing, Dynatrace CEO Rick McConnell disclosed the sale of 50,000 common shares of the company on June 13 at a price of $46.4079 per share.

16:36 EDT Chegg announces restructuring plan, laying off 23% of global workforce - The company states: "Chegg's strategy focuses on providing holistic and differentiated product offerings for students, blending academic and functional support that will include organizational proficiency, early career learning, financial literacy and community into one affordable platform designed to address gaps in the student experience. While other companies provide one-dimensional learning support or broad generic offerings, Chegg will differentiate itself through the development of a single platform that incorporates artificial intelligence verticalized for education, our proprietary learning model, more than 100 million pieces of content, subject matter experts who reinforce quality, and now functional 360-degree support services, which extend the value of Chegg beyond traditional online educational support. The restructuring includes the departure of 441 employees, which represents 23% of Chegg's global workforce. In 2025, the company expects to realize non-GAAP expense savings of $40 million to $50 million from employee departures, the closure of two offices outside of the United States, as well as other cost rationalizations. Chegg expects to incur a $10 million to $14 million charge related to the restructuring, with roughly half in the second quarter, and substantially the charges will be incurred by the fourth quarter of 2024."

16:32 EDT Lennar sees Q3 new orders 20,500-21,000 - Sees Q3: Deliveries 20,500-21,000; Average sales price $420,000-$425,000; Gross margin % on home sales about 23.0%.

16:31 EDT BWX Technologies awarded second phase of contract with Wyoming Energy Authority - BWX Technologies announced the award of the second phase of a contract with the Wyoming Energy Authority to assess the viability of deploying small-scale nuclear reactors in the state as a source of resilient and reliable energy to augment existing power generation resources. Under phase one of the program, BWXT Advanced Technologies LLC worked with the Wyoming Energy Authority to define the requirements for nuclear applications of base heat and power needs for remote, off-grid applications within the state. BWXT also performed microreactor system engineering work that could support Wyoming's future power needs and identified areas where Wyoming's existing supply chain could demonstrate capabilities for reactor component manufacturing and support reactor deployment. Phase two of the contract includes completing conceptual design of a lead microreactor unit, developing a regulatory engagement plan and microreactor fleet model, and demonstrating the Wyoming supply chain's ability to manufacture nuclear components. "BWXT has seen extraordinary support for the opportunities for microreactor deployment in Wyoming," said Joe Miller, BWXT Advanced Technologies LLC president. "Our meetings with numerous stakeholders have been very productive, and our workshops in Gillette, Cheyenne and Casper with potential local vendors have been well-attended. We look forward to taking this next step forward with the Wyoming Energy Authority and very much appreciate the vision of a clean, reliable and practical energy future demonstrated by both Governor Mark Gordon and the Authority's Executive Director Rob Creager."

16:23 EDT Bionano: AMA establishes new category I CPT code for OGM in malignacy analysis - Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, announced the editorial panel of the American Medical Association, AMA, established a new Category I Current Procedural Terminology CPT code for the use of optical genome mapping ,OGM, in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies. The CPT code is a key component in obtaining reimbursement for the OGM-Dx(TM) HemeOne laboratory developed test, LDT, from third party payers. The Category I CPT code is expected to be included in the next CPT codebook and to be effective January 1. The establishment of a new Category I CPT code for OGM implies that it has met the standards of acceptance by the medical community, in contrast to a Category III code, which is generally applied to emerging technologies. As part of the application review process, the panel collects input from stakeholders across the health care community to ensure CPT content reflects the coding and data-driven demands of modern health care.

16:18 EDT CytomX Therapeutics promotes Chris Ogden to CFO - CytomX Therapeutics announced the promotion of Chris Ogden to CFO effective June 15. Ogden joined CytomX in August of 2021 as VP, finance and accounting and has since served in roles of increasing responsibility spanning finance, accounting, investor relations, capital raising, information technology, and facilities, most recently as senior VP, finance and accounting.

16:16 EDT Earlyworks regains compliance with Nasdaq - Earlyworks received a written notification from the Nasdaq informing the company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2). The notification letter confirmed that the company's ADSs on Nasdaq had traded above $1.00 per ADS for 20 consecutive business days from May 16 to June 14 and that the company has regained compliance with the minimum bid price requirement.

16:12 EDT Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy - Procept BioRobotics announces that the American Medical Association has established a new Current Procedural Terminolog,y CPT, Category I code for transurethral waterjet resection of prostate tissue or quablation therapy, to treat benign prostatic hyperplasia n response to increased utilization of Aquablation therapy and strong evidence for its clinical outcomes, the AMA accepted PROCEPT BioRobotics' application for a Category I CPT code, which will replace the existing Category III CPT code starting January 1, 2026. In the meantime, U.S. hospitals and physicians performing Aquablation therapy procedures should continue to utilize the existing Category III code, 0421T. "We are pleased that Aquablation therapy was approved by the AMA's CPT Editorial Panel for Category I code status," said Reza Zadno, CEO of PROCEPT BioRobotics. "The Category I code designation is a testament to the widespread adoption, safety and effectiveness of Aquablation therapy in treating BPH. We greatly appreciate the support and guidance the American Urological Association provided throughout this process."

16:09 EDT OncoCyte appoints Andrea James to CFO - Oncocyte Corporation (OCX) announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. "We are thrilled to welcome Andrea as we approach the inflection point of commercial launch," Oncocyte CEO Josh Riggs said. "She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team. Prior to joining Oncocyte, Ms. James served as Chief Communications Officer and head of investor relations at Axon Enterprise (AXON). Ms. James worked in a strategic investor relations role for Tesla (TSLA) in 2016 and 2017. From 2009 to 2016 she worked as a sell-side analyst for Dougherty & Company becoming a vice president and senior research analyst. At Dougherty, she researched emerging technologies on behalf of institutional investors. Previously, she was a reporter at publications including Bloomberg News and the Seattle Post-Intelligencer covering a range of business and financial beats.

16:07 EDT iRhythm launches initial phases of manufacturing automation plans - iRhythm announced that the company has launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings. In this initial phase, iRhythm has implemented an autohandler machine to automate the testing of printed circuit board assembly, or PCBA, components of the recently-launched Zio monitor. This technology automates the functional testing of PCBAs, handles their movement to and from test fixtures, and separates passed and failed units, streamlining the manufacturing process and enhancing overall efficiency. Zio monitor was previously assembled and tested manually; the introduction of manufacturing automation enhances iRhythm's scalability for continued expansion in both the U.S. and international markets. Additionally, as the company anticipates that the new Zio monitor will serve as the foundational hardware platform for future technology iterations - including the next generation mobile cardiac telemetry product - automation will be crucial in keeping pace with the projected global demand for its Zio ECG monitoring products. The company anticipates that all phases of planned manufacturing improvements will enable capacity production of up to 10M units annually.

16:06 EDT Rexford Industrial announces CFO, COO transition plans - Rexford Industrial Realty announced that the company has initiated a process to recruit a new CFO and, upon the successful hire of a new CFO, to then elevate Laura Clark, the company's current CFO, to the newly-established role of COO. The company has initiated an executive search effort through Russell Reynolds Associates to identify and appoint a new CFO. Upon transition to COO, Clark will oversee the operational and growth segments of the Company including asset management, investments, development and construction, leasing, property management and marketing, among others.

16:05 EDT Keros Therapeutics appoints CEO Jasbir Seehra as Chair of Board - Keros Therapeutics announced changes to its Board of Directors and Executive Committee, effective July 1. Keros' Board has appointed Jasbir S. Seehra, Ph.D., Chief Executive Officer, as Chair of the Board, effective July 1 . Dr. Seehra will succeed current Chair Carl L. Gordon, Ph.D, C.F.A., who will remain an active Board member. Jean-Jacques Bienaime will serve as the Lead Independent Director of the Board, effective July 1. Additionally, Christopher Rovaldi has been promoted to President, effective July 1, 2024. Mr. Rovaldi succeeds Dr. Seehra, who served as the Company's President from December 2015 until June 30. Mr. Rovaldi will also continue serving as Chief Operating Officer of Keros. "I am honored to expand my role with Keros as the next Chair of its Board. I look forward to working with and leading our Board, which is comprised of directors with diverse backgrounds and extensive life sciences industry experience, in continued value creation for stockholders," said Dr. Seehra. "Separately, Chris has been an indispensable partner to me and an integral part of Keros' growth. With Chris in this new role, we will have additional leadership focus on our strategic and operational priorities across the company, which is critical as we prepare for the initiation of our first registrational Phase 3 clinical trial of elritercept in patients with lower-risk myelodysplastic syndromes."

16:02 EDT Heidrick & Struggles announces departure of CFO Mark Harris - Heidrick & Struggles announced that Mark Harris, CFO, has elected to depart the company to pursue other opportunities. The company has commenced a formal search for a new CFO, and Harris, who assumed the role in 2018, will remain with the company until August 2024 to ensure continuity and a successful transition.

15:42 EDT Musk says working on 'epic' Tesla 'Master Plan 4' - Tesla CEO Elon Musk tweeted: "Working on the Tesla Master Plan 4. It will be epic." Reference Link

15:17 EDT Cameco, SaskPower and Westinghouse announce MOU to explore reactor potential - Saskatchewan Power Corporation, or "SaskPower," Westinghouse Electric Company and Cameco have signed a memorandum of understanding, or MOU, to evaluate the potential of Westinghouse's nuclear reactor technology and the associated nuclear fuel supply chain required for Saskatchewan's future clean power needs. "The MOU will explore technical and commercial pathways to deploy Westinghouse's reactor technology, including the advanced AP1000 reactor and AP300(TM) small modular reactor (SMR), for long-term electricity supply planning. The framework includes evaluation of a Saskatchewan-based nuclear supply chain to support nuclear energy projects, including fuel. It also identifies opportunities to collaborate on nuclear research, development and workforce training in partnership with Saskatchewan's post-secondary institutions. SaskPower is expected to make its final investment decision in 2029 whether to proceed with constructing Saskatchewan's first SMR facility. The utility intends to use Saskatchewan uranium in any reactor constructed in the province," the companies stated.

14:43 EDT Autodesk up 7% after Starboard confirms stake, pushes for changes - Shares of Autodesk are up $16.12, or 7%, to $241.99 in afternoon trading after activist investor Starboard Value confirmed this morning that it has taken a stake in the company and expressed concerns.

14:10 EDT Matthews refutes Tesla allegations as 'utterly without merit' - Matthews International (MATW) notes that on Friday evening, June 14, Tesla (TSLA) filed a complaint in Federal District Court in the Northern District of California. "The claims stated in this threadbare complaint are utterly without merit and we intend to vigorously defend the matter. Notably, the complaint vaguely references trade secrets, but fails to identify even one trade secret that Tesla purportedly disclosed to Matthews. We are continuing to evaluate this complaint and may pursue legal remedies. Contrary to the allegations in the complaint, Tesla's lawsuit is simply a new tactic in their ongoing efforts to bully Matthews and improperly take Matthews' valuable intellectual property. Furthermore, Tesla's complaint attempts to restrict us from offering our innovative solutions to others, preventing the market from significantly benefiting from the savings associated with our dry battery electrode, or 'DBE,' solutions, and thus interfering with Matthews' ability to realize the value of our intellectual property. Over 25 years ago, before Tesla even existed as a company, our engineers began the development of breakthrough technology that forms the basis of our DBE solutions which streamlines production of lithium-ion batteries and significantly reduces production costs of electric vehicles. Five years ago, Tesla came to Matthews seeking engineering solutions and access to our valuable intellectual property, trade secrets and our global engineering talent. As the complaint acknowledges, Matthews continues to work with Tesla as a trusted supplier. For the reasons outlined herein, we do not currently believe the matters will have a material impact on the company," Matthews stated in a press release.

12:33 EDT FDA approves pembro plus chemo for endometrial carcinoma - The Food and Drug Administration approved pembrolizumab, or Keytruda, from Merck with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. Reference Link

12:07 EDT enVVeno Medical to present interim data from VenoValve trial - enVVeno Medical announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL. The presentation, entitled "The Impact of VenoValve Implantation on Venous Ulcer Healing in Patients with Deep Venous Reflux," will be made on Friday, June 21, 2024 by primary investigator Dr. Cassius Iyad Ochoa Chaar MD, MS, RPVI, Associate Professor of Surgery, Division of Vascular Surgery, Yale School of Medicine, the top enrolling site for the trial.The data to be presented will include venous ulcer healing and improvement rates for venous ulcer patients who have now reached the one-year milestone in the Company's Surgical Anti-reflux Venous Valve Endoprosthesis (U.S. pivotal study for the VenoValve. Overall healing or improvement rate data for thirty-one ulcers among twenty-one patients will be presented, and the presentation will also include sub-categories for ulcers that existed for more than one year and less than one year prior to the VenoValve surgery. Recurrence rate data for any venous ulcers that fully healed, and then recurred, will also be presented. Excerpts from the presentation will be made available on the Company's website. In assessing the benefit and risk of a novel technology such as the VenoValve, which addresses an unmet medical need, the U.S. Food and Drug Administration considers whether a medical device provides a clinically meaningful benefit compared to existing technologies. Subjects with venous ulcers who were enrolled in the SAVVE study all received at least three months of conventional treatment with existing technologies and many also received vein ablations for superficial venous disease, and venous stenting for obstruction, if indicated. As a result, the venous ulcer patients in the SAVVE study are the most difficult to treat, having venous ulcers that remained after at least three and as many as five types of existing treatments. The FDA has asked the Company to collect one year data on all SAVVE patients to support its PMA application seeking FDA approval to market and sell the VenoValve, which the Company expects to file in Q4 of this year.

12:05 EDT ZKH Group falls -9.8% - ZKH Group is down -9.8%, or -39c to $3.60.

12:03 EDT Sonida Senior Living rises 8.8% - Sonida Senior Living is up 8.8%, or $2.34 to $28.99.

12:01 EDT Xponential Fitness rises 25.8% - Xponential Fitness is up 25.8%, or $2.91 to $14.18.

11:45 EDT AP Acquisition Corp trading halted, news pending

11:03 EDT Gates Industrial names John Patouhas as SVP, chief accounting officer - Gates Industrial Corporation announced the appointment of John Patouhas as Senior Vice President and Chief Accounting Officer, effective June 17. Patouhas will be responsible for the strategic direction of Gates' accounting function, including financial reporting, risk, controls, and compliance in accordance with applicable standards, laws and regulations. "John brings significant manufacturing finance leadership experience to Gates and we look forward to the benefit of his background and expertise in ensuring a robust accounting and controls function as we continue to grow our business globally," stated EVP/CFO Brooks Mallard, adding "we are delighted John has chosen to join Gates." Most recently John served as Vice President, Chief Accounting Officer for automotive components manufacturer Tenneco.

10:43 EDT Mirum jumps after announcing interim results from two studies of volixibat - Shares of Mirum Pharmaceuticals are moving higher today after the company announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter inhibitor in patients with primary biliary cholangitis, or PBC, and primary sclerosing cholangitis, or PSC. Interim results from the VANTAGE study evaluating volixibat in patients with PBC demonstrated a statistically significant improvement in pruritus for volixibat and a placebo-adjusted difference of -2.32 points in the primary endpoint, as measured by the Adult ItchRO scale. 75% of patients on volixibat achieved a greater than 50% reduction in serum bile acids. In addition, there was a significant improvement in fatigue at week 16 with volixibat compared to placebo. No new safety signals were observed, and adverse events were similar between the 20 mg and 80 mg treatment groups. The most common adverse event was diarrhea with all cases mild to moderate, and mostly transient; one case resulted in discontinuation. Four patients experienced serious adverse events, including one in the placebo arm. There were no clinically meaningful changes in liver biomarkers. Based on these results, the VANTAGE PBC trial will continue with a volixibat dose of 20 mg twice daily. Concurrently, the interim analysis for the VISTAS PSC study was conducted and the independent data review committee recommended that the study continue with the selected volixibat dose of 20 mg twice daily, with no changes to the study. The criteria for continuation included safety as well as a predefined threshold for efficacy. The sponsor and investigators are blinded to the interim results and analysis. "The interim data from the VANTAGE study provide outstanding results in relation to what has been shown for treatment of pruritus in PBC," said Joanne Quan, MD, chief medical officer at Mirum. "With both VISTAS and VANTAGE advancing to enroll their confirmatory portions, we are excited about volixibat as a potential future option to help patients overcome one of the most prevalent and burdensome symptoms of these rare liver diseases." In Monday morning trading, shares of Mirum have advanced $3.55, or 14%, to $29.47.

10:32 EDT EVI Industries to acquire Laundry Pro of Florida, terms not disclosed - EVI Industries executed a definitive agreement to acquire Lakeland, FL based Laundry Pro of Florida, a distributor of commercial laundry products and a provider of related installation and maintenance services. The addition of Laundry Pro significantly increases EVI's market share in the state of Florida and includes an experienced team with longstanding customer relationships and strategically valuable product lines. The Company believes that combined with EVI's southeast operations, the rapid deployment of its customer facing technologies, and with other benefits of being an EVI company, Laundry Pro will enhance its customer value proposition and immediately yield growth and profitability for EVI. As is customary under EVI's operating model, Laundry Pro will operate under its existing name and with its current team to provide continuity to customers, employees, and vendor partners. For the twelve months ended May 31, 2024, Laundry Pro generated revenues of approximately $12M, which were derived from the sale of equipment, parts, and the performance of installation and maintenance services. Upon completion of the Laundry Pro acquisition, EVI will have acquired twenty-seven commercial laundry businesses. The transaction is expected to close upon the satisfaction of customary closing conditions. EVI expects Laundry Pro's results of operations to be accretive to its fiscal year ended June 30, 2025.

10:07 EDT Avis extends PGA Tour marketing partnership, adds Schauffele as ambassador - AVIS announced a multi-year extension of its partnership as the Official Rental Car Company of the PGA TOUR, PGA TOUR Champions and Korn Ferry Tour. The agreement, through 2028, will continue to provide rental vehicles for players, caddies, employees and fans at PGA TOUR-sanctioned events worldwide. AVIS has been an Official Marketing Partner and the preferred rental car company of the PGA TOUR since 2011. AVIS also tees off a two-year partnership with PGA TOUR sensation Xander Schauffele.

10:05 EDT ZKH Group falls -6.3% - ZKH Group is down -6.3%, or -25c to $3.74.

10:04 EDT Under Armour, University of Maryland enter enter 12-year partnership extension - The University of Maryland has renewed its partnership with Under Armour, extending its agreement for an additional 12 years through 2036. Tfootball team in the country to wear UA jerseys. UA has been the department-wide exclusive outfitter since 2009 and will continue to design and supply the training and game-day footwear, apparel, and equipment for Maryland's varsity athletic teams. The new agreement also extends the partnership to the University beyond the walls of the athletics department, providing Under Armour products to outfit club and intramural teams within the University's Department of Recreation and Wellness. Supporting and celebrating student-athletes is core to both UA and Maryland, and the partnership renewal is designed to help more athletes unleash their full potential and perform at their best. In addition to outfitting the Terrapin student-athletes, the comprehensive partnership includes integration into the brand's marketing, social media, in-store, and grassroots activations. The two will share a marketing commitment, and both organizations will collaborate to champion the student-athletes' success on and off the field.

10:02 EDT Li-Cycle rises 13.7% - Li-Cycle is up 13.7%, or 58c to $4.82.

10:01 EDT Xponential Fitness rises 22.9% - Xponential Fitness is up 22.9%, or $2.58 to $13.85.

10:00 EDT Aaron's rises 32.3% - Aaron's is up 32.3%, or $2.44 to $9.97.

09:53 EDT Primo Water rises 14.2% - Primo Water is up 14.2%, or $3.17 to $25.50.

09:50 EDT Aaron's rises 32.5% - Aaron's is up 32.5%, or $2.45 to $9.99.

09:47 EDT ZKH Group falls -4.9% - ZKH Group is down -4.9%, or -19c to $3.80.

09:46 EDT Trxade Health Inc trading resumes

09:41 EDT Nano Nuclear Energy Inc trading resumes

09:36 EDT Nano Nuclear Energy Inc trading halted, volatility trading pause

09:32 EDT TPG announces growth investment in K2 Medical, terms not disclosed - TPG announced a significant strategic growth investment in K2 Medical Research, an integrated clinical trial site platform specializing in central nervous system trials for leading pharma and biotech sponsors. TPG is partnering with K2's management team to continue building a world class research platform. Terms were not disclosed. Founded by CEO, Sean Stanton, and Chief Medical Officer, Brandon Lenox, DO, K2 operates several de novo clinical trial sites across Florida. The Company specializes in conducting multi-phase clinical trials in complex therapeutic areas including Alzheimer's, psychiatry, and liver disease, among others. K2's model is centered around strong site operators, and the Company has successfully differentiated itself by developing direct relationships with pharma and biotech sponsors, while executing an impressive de novo regional growth strategy.

09:17 EDT Catheter Precision receives purchase order for LockeT - Catheter Precision announced an additional purchase order for its newest product, LockeT. As previously announced the company has recently expanded its US sales and clinical team in preparation for the national product launch of LockeT.After a successful evaluation, the newest purchase order comes from Eisenhower Medical Center in Ranchero Mirage, California. This purchase order marks the third new hospital in California to issue a purchase order since the beginning of May, and the second in the United States to move beyond evaluation and approve orders for future use.

09:16 EDT Pineapple Energy interim CEO adds shares to his position - Scott Maskin, Interim CEO of Pineapple Energy, has purchased additional shares to his significant position as a show of good faith in the company's long-term viability within the residential and commercial renewables space.

09:15 EDT Vicinity Motor receives order for two Vicinity Classic buses - Vicinity Motor announced the receipt of a new purchase order from the Corporation of the Town of Orangeville in Ontario, Canada for two Vicinity Classic buses. Per the terms of the supply agreement, the Town of Orangeville ordered two of the Company's 32-foot Clean-Diesel Vicinity Classic buses for delivery in 2025. The Vicinity buses will service the three active transit bus routes throughout the town of Orangeville. Orangeville is a suburb community of roughly 30,000 people in the greater Toronto area.

09:14 EDT Gladstone Commercial executes lease at industrial property in PennsylvaniaHub Group - Gladstone Commercial Corporation (GOOD) announced that it has executed a 7-year, 2-month lease with Hub Group (HUBG) at its 966,753 SF industrial building in Taylor, Pennsylvania, commencing July 1, 2024. The property was purchased by Gladstone Commercial in 2014.

09:13 EDT Tharimmune announces Type C meeting with FDA for Phase 2 TH104 program - Tharimmune reports Type C meeting feedback from the U.S. Food and Drug Administration for its Phase 2 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene for moderate-to-severe pruritus or "uncontrolled itching" in primary biliary cholangitis, a rare form of liver disease with no known cure. TH104, the Company's lead clinical product candidate is designed to avoid the liver's first-pass metabolism of oral formulations and, as such, may be a preferred candidate for liver-related and other pruritogenic inflammatory conditions. The molecule has a dual mechanism of action that affects both the mu and kappa opioid receptors. These extensively studied receptors, when stimulated and/or inhibited by the body's endogenous ligands, have been implicated in human itch circuitry for certain conditions, specifically cholestatic liver conditions. Tharimmune's recently received Type C meeting feedback from the FDA confirmed the Company's plan to pursue a 505(b)(2) approval pathway for TH104, which permits inclusion of data from external studies when the active ingredient is already approved in the United States. The FDA also agreed that the nonclinical studies submitted to the FDA in advance of the meeting appear sufficient to support the proposed Phase 2 clinical trial. In addition, the FDA provided feedback on study design and certain recommendations regarding PBC patient inclusion, the primary endpoint to assess pruritus in these patients, and considerations for monitoring for adverse events in this patient population. Based on this interaction, the Company believes it has a path forward to a Phase 2 trial with TH104 in moderate-to-severe chronic pruritus in PBC patients and is currently incorporating feedback from the FDA into its clinical protocol and anticipates initiating the trial in the latter part of 2024.

09:10 EDT Sellas Life Sciences says IDMC recommends continuation of Phase 3 REGAL trial - SELLAS Life Sciences Group announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S in acute myeloid leukemia by the Independent Data Monitoring Committee. The IDMC conducted a prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. Based on a detailed analysis of all unblinded data, the IDMC projects with a high level of confidence that the interim analysis will occur by the fourth quarter of 2024.

09:08 EDT LPL Financial announces Russell Wealth Partners joins Linsco - LPL Financial announced that financial advisor Tom Russell and his sons Brian Russell and Charles Russell have joined LPL's employee advisor channel, Linsco by LPL Financial, to launch Russell Wealth Partners. The family team reported serving approximately $250 million in advisory, brokerage and retirement plan assets* and joins LPL from Merrill Lynch. They will operate out of the Linsco suite at LPL's San Diego campus. With 38 years of industry experience, Tom Russell has always had a keen interest in market conditions and helping families work toward financial success. His sons Charles and Brian also recognized their passion for wealth management and followed their father's footsteps after initial forays in engineering and law, respectively.

09:07 EDT Nvidia announces NVIDIA Omniverse Cloud Sensor RTX - NVIDIA announced NVIDIA Omniverse Cloud Sensor RTX, a set of microservices that enable physically accurate sensor simulation to accelerate the development of fully autonomous machines of every kind. Sensors, which comprise a growing, multibillion-dollar industry, provide autonomous vehicles, humanoids, industrial manipulators, mobile robots and smart spaces with the data needed to comprehend the physical world and make informed decisions. With NVIDIA Omniverse Cloud Sensor RTX, developers can test sensor perception and associated AI software at scale in physically accurate, realistic virtual environments before real-world deployment - enhancing safety while saving time and costs.

09:07 EDT NBCUniversal expands partnership with Group Black - NBCUniversal, a subsidiary of Comcast (CMCSA), announced it has expanded its partnership with the inclusive mission-driven media company, Group Black, and will launch a new content collection on Peacock. This destination, E!+, will focus on programming that resonates with multicultural audiences and will officially launch later this year. In collaboration with NBCUniversal, Group Black will develop original content alongside the leading media and entertainment company's acclaimed programming and the Black Excellence 365 initiative.

09:06 EDT Nutanix names Brian Martin as Chief Legal Officer - Nutanix announced that it has named Brian Martin as Chief Legal Officer, effective June 18. With more than 20 years of experience in legal leadership roles, Martin has a proven track record of managing large, multinational teams while developing legal department personnel into company leaders at B2B technology businesses. In previous roles, he has helped drive transitions to cloud services and has consistently driven engagement among his teams while building legal functions as a competitive advantage and making it easier to do business in deep engineering cultures. "It is my philosophy that through the delivery of strategic and sensible legal counsel, a legal department will provide a competitive advantage to a company," said Brian Martin, Chief Legal Officer at Nutanix. "I am honored to work with the world-class legal team at Nutanix and look forward to helping drive forward the company's unrivaled innovation and execution." "Brian has a wealth of experience in driving the ethical and legal achievement of business objectives," said Rajiv Ramaswami, President and Chief Executive Officer at Nutanix. "We are proud to welcome him to Nutanix as he will guide trust, transparency, and compliance with our employees, customers, partners, investors, and regulators."

09:05 EDT iTeos Therapeutics, GSK initiate GALAXIES Lung-301 Phase 3 study - iTeos Therapeutics, Inc. (ITOS) and its development partner GSK (GSK) have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer. The randomized, double-blind, placebo-controlled, multicenter trial will enroll approximately 1,000 patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC in North America, South America, Europe and Asia. The primary endpoints of the trial are progression free survival and overall survival. In the GALAXIES Lung-301 trial, patients will be randomized 1:1 to either an intravenous infusion of the belrestotug + dostarlimab doublet or placebo + pembrolizumab.

09:05 EDT Archer Aviation, Signature Aviation sign MOU - Archer Aviation and Signature Aviation announced the signing of an MOU focused on electrifying Signature's network of over 200 airport terminals, giving Archer access to takeoff and landing sites in major metropolitan areas across the U.S. and globally, including New York, Los Angeles, San Francisco Bay Area, and Texas. The MOU identifies day-one opportunities for launching Archer's air taxi service in key United Airlines hubs at Newark International, or EWR, and Chicago O'Hare, or ORD, Airports. The two companies plan to leverage their existing partnerships with BETA Technologies to install BETA's interoperable rapid recharging systems across Signature's network of private aviation terminals. These systems utilize the Combined Charging System, or CCS, which can charge electric aircraft, cars, airplane tugs, buses, and other forms of transportation commonly used at airports.

09:03 EDT FirstService Residential announces promotion of Hagopian to SVP - FirstService Residential, a subsidiary of FirstService, has promoted Noushig Hagopian to Senior Vice President, SVP, of the New England market. Previously, Hagopian served as a Vice President.

09:02 EDT MyMD Pharmaceuticals appoints Mitchell Glass as chief medical officer - MyMD Pharmaceuticals announced the appointment of Mitchell Glass, a member of the board of directors of the company, as president and chief medical officer. The company also announced the appointment of Stephen Friscia, a veteran investor, to the board of directors.

09:00 EDT Sachem Capital announces registerd public offering of notes - Sachem Capital announced the commencement of a registered public offering of USD-denominated unsecured, unsubordinated Notes due five years from the date of issuance, subject to market conditions. The Notes are anticipated to be rated BBB+ by Egan Jones, Egan-Jones Ratings Company, an independent, unaffiliated rating agency, although this is contingent on prevailing market conditions. Egan-Jones is a Nationally Recognized Statistical Ratings Organization and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider. Egan-Jones is also certified by the European Securities and Markets Authority. A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. The company has mandated Oppenheimer & Co. Inc. as the sole-bookrunning manager for the offering.

08:59 EDT Evaxion Biotech announces publication of data from Phase 1 study of EVX-01 - Evaxion Biotech announces publication of data from its Phase 1 dose escalation study of its lead personalized cancer vaccine candidate, EVX-01, for metastatic melanoma. The study results, published in the Journal for ImmunoTherapy of Cancer, demonstrated that eight out of 12 patients experienced objective clinical responses with six partial and two complete responses. Further, EVX-01 immunization did not induce vaccine-related serious adverse events in patients co-administered with anti-PD1 therapy. The EVX-01 cancer vaccine is designed to target neoantigens - antigenic sequences derived from cancer mutations - that are displayed on the surface of cancer cells, allowing the immune system to recognize, attack and eliminate the malignant cells. Since the neoantigen tumor profiles vary from one cancer patient to another, the EVX-01 cancer vaccine is truly personalized and tailored to the unique characteristics of each patient's tumor and immune system profile. This represents a novel treatment paradigm with potential broad application in cancer therapy. At this year's ASCO annual meeting, the Company presented comprehensive immune data from its ongoing EVX-01 Phase 2 study, with 71% of the administered neoantigens inducing a specific T-cell response. Furthermore, a positive correlation between the neoantigen prediction score assigned by AI-Immunology and the reported induced immune response confirmed the Phase 1 study findings and further substantiated the predictive power of Evaxion's AI platform.

08:57 EDT Triumph Financial, C.H. Robinson enter strategic partnership - Triumph Financial, Inc. (TFIN) and global logistics provider C.H. Robinson (CHRW) announced a strategic relationship focused on delivering innovative payment solutions to the transportation industry. C.H. Robinson will join the TriumphPay Network, a platform that connects brokers, shippers, factors and carriers for a streamlined payment experience. This collaboration provides the foundation for delivering new solutions and financial benefits to carriers at a scale never seen before.

08:54 EDT Aerovate Therapeutics says AV-101 did not meet primary endpoint in IMPAHCT trial - Aerovate Therapeutics announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial, a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension. The objective of the Phase 2b portion of IMPAHCT was to assess the efficacy, safety and tolerability of three different doses of AV-101 compared to placebo. The primary endpoint for the Phase 2b portion of IMPAHCT is change in PVR compared with placebo. Results showed that, while AV-101 was well tolerated across all dose groups, the study did not meet its primary endpoint for improvement in PVR compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance The Company has also reviewed data from several additional secondary endpoints of the Phase 2b portion of IMPAHCT, which also failed to show meaningful improvements. Based upon these results, Aerovate, in agreement with the independent study advisory committee, is halting enrollment and shutting down the Phase 3 portion of IMPAHCT as well as the long-term extension study. Aerovate plans to release full data from the Phase 2b portion of IMPAHCT at a later date, the timing of which is to be determined.

08:52 EDT MSA Safety debuts latest Flame Detector solution - This week at the National Fire Protection Association, NFPA, Conference & Expo, MSA Safety is debuting its latest solution to help protect people and facility infrastructures: the MSA General Monitors FL5000 Multi-Spectrum Flame Detector. This newest detector, along with MSA Safety's leading gas and flame detection solutions portfolio, will be on display at the NFPA Conference & Expo in Orlando, Florida.

08:50 EDT Orrstown Financial, Codorus Valley receive regulatory approvals for merger - Orrstown Financial Services and Codorus Valley Bancorp have received the requisite regulatory approvals and waivers from the Board of Governors of the Federal Reserve System and the Pennsylvania Department of Banking and Securities for their previously announced merger of equals. The parties anticipate closing the transaction on July 1, 2024, subject to the satisfaction of customary closing conditions.

08:49 EDT Evoke Pharma reports commercial strategy progress for GIMOTI - Evoke Pharma announced updates regarding their business and commercial growth strategy. With a determined focus to ensure maximum market access for GIMOTI, Evoke continues to execute on its plan to expand net product sales throughout 2024. This update outlines the key areas of Evoke's strategic blueprint and positive updates regarding its implementation. In November 2023, Evoke transitioned its pharmacy distribution partnership from vitaCare to ASPN Pharmacies. This strategic move has streamlined the prescription process for healthcare providers, ensuring that patients receive GIMOTI promptly. Over two quarters of collaboration with ASPN, Evoke has improved percentages of GIMOTI prescriptions converted to fills, and initial data show record-high prescription fills in April and May. ASPN's comprehensive servicing platform provides holistic advantages for our business, healthcare providers, and patients, reinforcing Evoke's mission to reach as many patients as possible In May 2024, Evoke, through Eversana, began expanding our filling pharmacy network from a single central organization to an additional four regional pharmacies. This is intended to allow for improved coverage, reimbursement and speed to deliver GIMOTI to patients in need. Some of the states where access to GIMOTI will improve based on expanded distribution include: Arkansas, Connecticut, Georgia, Illinois, and Michigan, Mississippi, Rhode Island and Tennessee. In our first full month with these additional pharmacies, Evoke is already realizing additional GIMOTI covered prescriptions through insurers, especially Medicaid patients. Evoke anticipates further expansion of our pharmacy distribution in the coming months.

08:47 EDT Rennova Health enters stock exchange agreements with Foxo Technologies - Rennova Health (RNVA)has entered into two stock exchange agreements with FOXO Technologies (FOXO). In the first agreement, Rennova's equity in Myrtle Recovery Centers, Inc., the Company's behavioral health services subsidiary, was exchanged for $500,000 of common stock in FOXO. In the second agreement, equity in Rennova Community Health, Inc., predominantly consisting of the Company's critical access hospital, will be exchanged for $20 million of convertible preferred stock in FOXO. Closing of the Myrtle transaction took place on June 14, 2024 and closing of the Rennova Community Health transaction, subject to certain closing conditions including shareholder approvals, is expected to be completed in the third quarter of 2024. In addition, FOXO secured a commitment for up to $2.5 million of financing of which $750,000 was funded at the Myrtle closing.

08:45 EDT Orrstown Financial, Codorus Valley receive regulatory approvals for merger - Orrstown Financial Services (ORRF) and Codorus Valley Bancorp (CVLY) announced that they have received the requisite regulatory approvals and waivers from the Board of Governors of the Federal Reserve System and the Pennsylvania Department of Banking and Securities for their previously announced merger of equals. The parties anticipate closing the transaction on July 1, 2024, subject to the satisfaction of customary closing conditions.

08:42 EDT Freddie Mac to offer social bonds issuance supporting disability housing - Freddie Mac Multifamily will soon go to market with the issuance of $186 million in Social Bonds supporting 641 rental homes for individuals with intellectual and developmental disabilities across 26 states. The proceeds from these Social Bonds help address the significant shortage of community-based homes critical to the deinstitutionalization of care for individuals with disabilities. The properties provide 2,633 beds, with approximately 79% of beds affordable to people with very low incomes making 50% of the area median income or below, ensuring more individuals with disabilities can live and work in their communities. This Social Bond structured transaction is a PC-REMIC, Series 2024-P016, issuance backed by a pool of six Multifamily Participation Certificates.

08:41 EDT Starboard confirms Autodesk stake above $500M, concerned with operations - In a shareholder letter, Starboard stated: "We believe Autodesk has continued runway for growth, with incredibly sticky solutions that are the industry standard and integral to how its customers work, as well as an opportunity to expand further into attractive new verticals, such as construction. We also believe Autodesk has an opportunity to create significant shareholder value by meaningfully improving its combination of growth and profitability through substantial margin improvement, as well as adopting more shareholder-friendly capital allocation policies and improving governance and oversight. Despite our belief in the strong long-term prospects of Autodesk, we have significant concerns with the Company's operations, governance, oversight, and accountability to shareholders, given its lengthy history of missed commitments and underperformance from an operational and financial perspective. Our concerns were exacerbated by the recently disclosed findings from the Company's Audit Committee Investigation into Autodesk's accounting and disclosures. The Investigation's findings raise significant issues and questions about the Company's accounting and disclosure practices, executive compensation practices, and oversight, or a lack thereof, from the Board of Directors. Even more concerningly, it appears that the Board chose to withhold material information from shareholders ahead of the nomination deadline in order to preserve the status quo and insulate the incumbent directors from a potential challenge by shareholders."Reference Link

08:40 EDT Sharps Technology ships first orders for Securegard to Colombian partner - Sharps Technology has made the first shipment of its 1mL and 3mL Securegard smart safety syringe line to the Latin American healthcare market. The initial product orders were placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region. Tapping into the growing interest in safety syringe technology in Latin America, the collaboration will make the Securegard syringe line available to hospitals, pharmacies, and direct points of sale and will give healthcare networks access to utilizing the technology and firsthand experience with its real-world benefits.

08:39 EDT Maxeon Solar to showcase latest solar energy innovations - Maxeon Solar Technologies announced its presence at Intersolar Europe 2024 June 19-21, where it will showcase its latest SunPower branded energy solutions and solar panel technologies at Booth A1.350 Maxeon will be exhibiting its residential home energy system, featuring a suite of products and services that empower consumers to manage and optimise their home energy consumption and the use of self-generated clean energy. Products on display include its new Maxeon 7 solar panels pioneering the future of PV technology, Performance 7 solar panels, SunPower Reserve battery storage and SunPower Drive EV charging

08:38 EDT First Western Financial announces stock repurchase program up to 200,000 shares - First Western Financial announced that on June 13, 2024 its Board of Directors approved a stock repurchase program that authorizes the Company to repurchase up to 200,000 shares of its common stock, which represents approximately 2% of the Company's outstanding shares. The Board of Governors of the Federal Reserve System advised the Company that it has no objection to the Company's stock repurchase program.

08:37 EDT Tegna CEO David Lougee to retire, Michael Steib to succeed - Tegna announced that Michael Steib will succeed David Lougee as president, CEO and a director as of August 12. At that time, Lougee will retire from these roles and become senior advisor. Steib is currently CEO of Artsy.

08:36 EDT Wearable Devices to unveil XR integration with Qualcomm at AWE 2024 - Wearable Devices announced the showcase of its latest capabilities in Extended Reality integration in collaboration with Qualcomm Technologies at the Augmented World Expo 2024. This partnership demonstrates the synergy between Wearable Devices' innovative wearable solutions and Qualcomm's state-of-the-art XR technology, promising to revolutionize the immersive experience for consumers and enterprises alike. AWE 2024 will take place on June 18-20, 2024 in Long Beach, California. At the heart of this showcase is the seamless integration of Wearable Devices' advanced neural input technology with Qualcomm's cutting-edge XR hardware and software solutions. This collaboration, which began a few months ago, aims to enhance user interaction and engagement by leveraging the strengths of both companies in wearable tech and XR platforms.

08:35 EDT Xponential Fitness appoints Mark King as CEO - Xponential Fitness (XPOF) announced that its board of directors has unanimously appointed Mark King as CEO effective June 17. King will also join the Company's board of directors. At that time, Brenda Morris will cease serving as interim CEO but will continue to serve as a member of the company's board of directors. Most recently, as CEO of Taco Bell (YUM), he led the franchisor to positive same-store sales growth in each quarter but one under his leadership while simultaneously opening more than 1,400 new franchise locations.

08:34 EDT Amwell appoints Ricky Goldwasser to board of directors - Amwell announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. Ms. Goldwasser has spent her career advising institutional investors and public and private companies across the healthcare services continuum. She spent 15 years at Morgan Stanley where she was a managing director, head of U.S. Healthcare Services & Technology Research and most recently Investment Banking groups, and was co-head of U.S. Healthcare Research at UBS.

08:32 EDT Marex Group to offer client clearing of interest rate swaps - Marex announces it will offer client clearing of interest rate swaps. It will become a member of LCH's SwapClear service, one of the largest interest rate swaps clearing houses in the world, on July 15, 2024, subject to final approval. As the first non-bank Futures Commission Merchant clearing member to offer client clearing of interest rate swaps through the LCH SwapClear service, Marex is addressing a gap in the market and responding to client demand for greater counterparty risk diversification, clearing capacity and improved market connectivity. Marex's client clearing of interest rate swaps expands its existing clearing memberships across energy, commodity and financial markets, and signals its commitment to continually invest in its clients and grow its platform. Marex's non-bank clearing solution is broker agnostic and can complement existing bank relationships.

08:30 EDT Solid Power reaffirms 2024 outlook - Solid Power previously reported strong execution in the first quarter of this year, delivering on both partner commitments and development timelines. The company has seen growing interest in its electrolyte product, has successfully shipped electrolyte samples, and is making meaningful progress towards its target delivery of A-2 sample cells by the end of the year. With its strong financial position, the company aims to expand its electrolyte capabilities and available markets, advance A-2 sample cell designs, and strengthen its presence in Korea in 2024, all while continuing to execute on its key strategic milestones. Solid Power is reaffirming its 2024 guidance provided in its first quarter 2024 earnings materials on May 7, 2024. The company continues to expect 2024 cash used in operations to be in the range of $60 million to $70 million and capital expenditures to be in the range of $40 million to $50 million. Included in these ranges is approximately $35 million in operational and capital investments the company deferred from 2023. Total 2024 cash investment is expected to be in the range of $100 million to $120 million. 2024 revenue is still expected to be in the range of $20 million to $25 million.

08:28 EDT Scorpius Holdings receives NYSE American delisting notice, plans to appeal - Scorpius Holdings reported that it received notice from the NYSE American of its determination to commence delisting proceedings of the Company's common stock from the exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low-selling price of the Company's common stock. The Company plans to appeal the determination to the Exchange's Listing Qualifications Panel, although there can be no assurance of a successful outcome.

08:26 EDT SunCar Technology partners with Ping An Insurance Group - SunCar Technology Group announces a new strategic collaboration with Ping An Property & Casualty Insurance Co., a subsidiary of Ping An Insurance Group Co. of China, one of the five largest insurance companies in the world and a long term enterprise client of SunCar's. This partnership aims to enhance the airport pickup services provided to Ping An's high-value clients, reflecting SunCar and Ping An's continued commitment to excellence and customer satisfaction. Under this new agreement, Ping An P&C Shenzhen becomes the seventh branch of Ping An to partner with SunCar for this premium service, joining the ranks of Guangdong, Fujian, Ningbo, Shanghai, Beijing, and Shanxi branches. This agreement with SunCar supports Ping An's commitment to offering premium value-added services to its clients, fostering long-lasting relationships.

08:25 EDT BranchOut Food signs purchase agreement for EnWave dehydration machine - BranchOut Food Inc. (BOF) has signed a purchase agreement for a 10kW Radiant Energy Vacuum machine, built by EnWave Corporation (NWVCF). The machine will be installed at BranchOut Food's new, large-scale facility in Peru and will be used for R&D, rapid product development and production scale-up in response to new product requests from major retailers and large brands.

08:24 EDT Elutia announces FDA clearance of EluPro - Elutia announced that its Antibiotic-Eluting BioEnvelope, EluPro has received clearance from the U.S. Food and Drug Administration. Specifically designed to prevent post-operative complications for devices such as pacemakers and defibrillators, EluPro incorporates powerful antibiotic therapy combined with advanced tissue engineering to create a BioEnvelope that over time regenerates into a protective pocket of the patient's own tissue. Infection, migration, and skin erosion are some of the most frequently encountered complications of pacemaker surgery, occurring in up to five to seven percent of cases. These cause significant patient morbidity and mortality, increase the length of hospitalization, and can add more than $50,000 to healthcare costs per event. In development since 2019 and protected by intellectual property extending beyond 2032, EluPro is the only biologic offering in the $600 million U.S. implantable electronic device protection market. The Company also announced that EluPro was granted clearance for indications beyond the cardiac implantable electronic devices, including neurostimulators and neuromodulators used for pain management, epilepsy, incontinence, and sleep apnea. These additional markets, estimated to be $8 billion worldwide, have not previously been served by a drug-eluting biomatrix and present significant additional growth opportunities for EluPro.

08:23 EDT Bluejay Diagnostics announces 1-for-8 reverse stock split - Bluejay Diagnostics Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-8. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on June 20, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on June 20, 2024 under the Company's existing trading symbol, "BJDX." At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633400.

08:21 EDT Assembly Biosciences announces $12.6M in equity financings - Assembly Biosciences (ASMB) closed the issuance of shares of its common stock and warrants to Armistice Capital and Gilead Sciences, Inc. (GILD), in separate equity financings that have resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million, before deducting expenses. The sale of common stock to Gilead maintains Gilead's ownership of 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing pursuant to the terms of the Investor Rights Agreement entered into between Assembly Bio and Gilead in October 2023. Assembly Bio and Gilead have also agreed to extend the time period to satisfy certain conditions related to Assembly Bio's right to require Gilead to increase its ownership from 19.9 percent up to 29.9 percent of Assembly Bio's outstanding voting stock at a premium. Assembly Bio sold 634,500 shares of common stock and warrants to purchase up to 634,500 shares to Armistice Capital, and sold 179,500 shares of common stock and warrants to purchase up to 179,500 shares to Gilead, in each case, at a combined price of $15.46 per share of common stock and accompanying warrant. The warrants have an exercise price of $17.00 per share of common stock, will be immediately exercisable and will expire on June 18, 2029. Assembly Bio currently expects to use the net proceeds from the equity financings for general corporate purposes.

08:19 EDT Solowin Holdings becomes largest holder of multiple virtual asset ETFs - SOLOWIN HOLDINGS announced that Solomon JFZ has become the largest holder of customer assets in the ChinaAMC Bitcoin ETF, ChinaAMC Ethereum ETF, and Harvest Bitcoin Spot ETF. In addition, Solomon is also among the top holders of ChinaAMC Bitcoin ETF and ChinaAMC Ethereum ETF.

08:16 EDT Tonix Pharmaceuticals presents poster on Tomnya for fibromyalgia management - Tonix Pharmaceuticals Holding presented data from a poster presentation at the Annual European Congress of Rheumatology 2024, held June 12-15, 2024 at the Messe Wien Congress Center in Vienna, Austria. A copy of the Company's poster presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com. In the poster presentation titled, "Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial", Tonyma met the pre-specified primary endpoint in the Phase 3 RESILIENT trial, significantly reducing daily pain compared to placebo in participants with fibromyalgia while also demonstrating broad syndromal improvement. Tonmya demonstrated statistically significant improvement in all six pre-specified key secondary endpoints including those related to improving sleep quality, reducing fatigue, and improving patient global ratings and overall fibromyalgia symptoms and function. Tonmya was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed. In pre-specified exploratory analyses, Tonmya treatment also improved depressive symptoms measured by the Beck Depression Inventory and improved female sexual function by the Changes in Sexual Function Questionnaire in the RESILIENT trial. Tonix remains on track to submit an NDA to the U.S. Food and Drug Administration in the second half of 2024 for Tonmya for the management of fibromyalgia.

08:13 EDT Dycom CEO Steven Nielsen to retire in November, Daniel Peyovich to succeed - Dycom Industries announced that after 25 years of service as CEO Steven Nielsen will retire on November 30, 2024. In preparation for his retirement, Mr. Nielsen worked closely with the Board of Directors on a comprehensive multi-year succession plan. As a result of that process, Daniel Peyovich, the Company's Executive Vice President and COO, has been appointed the Company's next CEO, effective upon Mr. Nielsen's retirement. Nielsen remains CEO and Chair of the Board until his retirement, at which point he will step down as a director. Mr. Peyovich has also been appointed President of the Company, effective today, and he is expected to join the Board on November 30, 2024. Additionally, the Board has voted to designate Richard K. Sykes, Dycom's current Lead Independent Director, as the Company's next Chairman, with the appointment effective following Mr. Nielsen's retirement.

08:10 EDT Satixfy Communications awarded over $20M contract from undisclosed customer - SatixFy Communications announced it has secured a significant order from an undisclosed customer. Under the terms of the order, SatixFy will be supplying Prime2 Space-Grade chips and software over the coming five quarters in exchange for payment from the customer to SatixFy of more than $20M. This is a follow up order to an earlier $4M order from September 2023. The Prime2 Space-Grade chip is a digital beamformer Application-Specific Integrated Circuit, or ASIC, designed for massive MIMO antennas in space, and serves as a cornerstone for complex satellite communication systems.

08:10 EDT Rallybio reports results from epidemiological analysis evaluating FNAIT risk - Rallybio reported topline results from an epidemiological analysis of large genomic datasets evaluating the frequency of fetal and neonatal alloimmune thrombocytopenia FNAIT risk in diverse ancestries. Data from this analysis confirmed Caucasian populations as having the greatest proportion of women with the genetic markers for higher FNAIT risk . Additionally, data from this analysis provides, for the first time, robust evidence quantifying the proportion of women in non-Caucasian ancestries that carry the genetic markers for higher FNAIT risk. These data indicate that the proportion of pregnant women at higher risk for FNAIT annually has been significantly underestimated. For example, in key geographies of North America and major European countries, it is estimated that more than 30,000 pregnancies each year are at higher risk for FNAIT, representing a 40% increase from prior estimates. Full data from the epidemiological analysis are expected to be presented at a scientific conference in the fourth quarter of 2024. "This epidemiological analysis leverages the availability of large-scale, diverse genomic datasets, and provides the first clear evidence of the extent to which ancestries beyond the Caucasian population can carry a higher risk for FNAIT," said Stephen Uden, MD, Chief Executive Officer of Rallybio. "These data indicate that FNAIT risk is more prevalent than previously estimated and highlights the importance of screening. Unlike many other rare diseases, we believe that screening for FNAIT risk could be seamlessly incorporated into standard prenatal care for all mothers. This would ensure all women at higher risk for FNAIT could then be offered prophylactic treatment with RLYB212, if approved."

08:08 EDT Xwell opens XpresSpa location at Philadelphia International Airport - XWELL announced the grand opening of its newest XpresSpa location in Philadelphia International Airport. With more than 28 million passengers annually, the new PHL XpresSpa represents an exciting opportunity to drive revenue growth with its labor lite and tech forward offerings.

08:07 EDT Infinera, DZS, Calnex demonstrate 5G Mobile xHaul with open XR optics - Infinera announced a multi-vendor demonstration of 5G mobile broadband xHaul using coherent open XR optics point-to-multipoint optical transmission. The multi-vendor interoperability testing, conducted with DZS and Calnex, represents a key step toward enabling mobile operators to greatly simplify and cost-reduce 5G and next-generation mobile transport network rollouts through the reduction of the number of optical transceivers, resulting in significant total cost of ownership savings. Hosted in the European Open Test & Integration Center in Torino by TIM, the high-capacity xHaul application testing included fronthaul, midhaul, and backhaul transport scenarios with XR-based coherent pluggable optics deployed in third-party hosts supporting point-to-point and point-to-multipoint optical transmission. Results of the performance testing included successful demonstration of xHaul synchronization and timing distribution in a point-to-multipoint optical transport architecture.

08:06 EDT DigitalOcean names Bratin Saha chief product, technology officer - DigitalOcean (DOCN) announced Bratin Saha has joined the company as its chief product and technology officer, or CPTO. In this new executive role, Saha will lead product strategy, development, infrastructure, and security. Saha joins from Amazon Web Services (AMZN), where he served as VP and GM of artificial intelligence, machine learning and data infrastructure.

08:05 EDT Labcorp launches Global Trial Connect to accelerate clinical trials - Labcorp announced the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted - investigator sites. "The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investigator workflow, improves the patient experience and ultimately enables biopharma sponsors to bring therapies to market faster," said Jon DiVincenzo, EVP and President, Central Laboratories and International at Labcorp. "As the world's leading central laboratory, Labcorp is dedicated to improving the pace of clinical trials focusing on the investigator site experience from study initiation to patient recruitment and data collection."

08:04 EDT Atara Biotherapeutics announces 1-for-25 reverse stock split - Atara Biotherapeutics announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. Eastern Time, on June 20. The company's common stock will begin trading on a post-split basis at the market open on June 20. The reverse stock split is part of the company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on Nasdaq, among other benefits.

08:03 EDT Certara launches next-generation CoAuthor generative AI software - Certara unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers. It combines generative AI, document templates, Microsoft Word integration, and structured content authoring tools. CoAuthor accelerates the creation of regulatory documents while maintaining a "human in the loop" approach to the use of generative AI.

08:01 EDT Cognizant, Gentherm sign agreement for strategic engineering services - Cognizant (CTSH) announced an agreement to provide engineering services to Gentherm (THRM). Cognizant is providing systems engineering, validation, and model-based development services from Hyderabad, India, and has created a test facility to conduct research and development for Gentherm products. "One of the keys to unlocking innovation is creating a culture of collaboration among automakers, suppliers and technology companies," said Vishnu Sundaram, Gentherm's CTO. "As we deliver solutions to address the needs of our customers, including the growing needs of software-defined vehicles, Cognizant will be an invaluable innovation partner to extend our technology leadership."

07:43 EDT Else Nutrition completes rollout of RTD Kids Shakes in 276 retail locations - ELSE NUTRITION announced the successful rollout of its new ready-to-drink kids shakes at a major Midwest retailer, making products available in the retailer's 276 locations. Else Nutrition's complete product line hit the shelves the first week of June 2024.

07:41 EDT Qiagen sets goal for at least $2B of combined annual sales in 2028 - The 2028 strategy involves the following:Sharpen focus on growth pillars to sustain profitable growth: QIAGEN has set a goal for at least $2 billion of combined annual sales in 2028 from its pillars amid plans for new product launches and important investments: QIAcuity digital PCR: QIAGEN is more than tripling the number of sales specialists supporting QIAcuity to drive adoption as over 100 new assays are launched. The QIAcuity-Dx version is also planned to receive U.S. regulatory clearance in 2024 for clinical use, with submission of an assay for detection of the BCR-ABL biomarker for onco-hematology planned for 2025. QIAGEN also signed its first companion diagnostic agreement for QIAcuity with an undisclosed pharma partner. QIAstat-Dx: QIAGEN confirmed plans for the U.S. regulatory submission of a new panel for syndromic diagnosis of meningitis in 2024 to complement the European version, building on the recent U.S. regulatory approval of the gastrointestinal panel and upgraded respiratory panel. QIAGEN also plans for the U.S. and European submissions of three panels by 2028 involving blood culture, complicated urinary tract infections and pneumonia. Also in the U.S., new "mini panels" are planned to be submitted for U.S. regulatory approval in 2024. These new panels will enable the diagnosis of five pathogens causing respiratory or gastrointestinal conditions, and are designed to address customer demands. QIAGEN Digital Insights: QIAGEN confirmed plans to accelerate investments into this business with at least nine new product launches planned by 2028. These plans also include a 40% expansion in the commercial team to extend the global presence into new geographic markets. QIAGEN intends to continue investing about 20% of QDI sales into R&D to combine the power of AI and human-curated knowledge bases, with plans to grow from the current 5 AI-enabled applications across the portfolio to at least 14 by 2028. Sample technologies: Two important new instrument launches are planned along with several new consumables kits to strengthen QIAGEN's leadership in this important first step of lab workflows. QIAsymphony Connect is planned for launch in 2025 as an upgrade of the flagship QIAsymphony automation system, building on over 3,300 cumulative placements. QIAGEN also plans to enter the high-throughput automation market with the launch of QIAsprint Connect in 2026. New kits are planned for use on QIAGEN's full portfolio of instruments in high-growth applications including liquid biopsy, microbiomes and pathogen detection. QuantiFERON: QIAGEN is a key enabler of the global initiative to eradicate tuberculosis, a potentially fatal bacterial infection, through its QuantiFERON-TB Gold Plus test. About 60% of the global market for annual latent TB testing remains available for conversion from the tuberculin skin test, as QIAGEN steps up commercialization initiatives backed by its best-in-class test and top automation solution with partners DiaSorin, Tecan and Hamilton. QIAGEN is also partnering with DiaSorin on a test for detection of Lyme Disease, which is available in Europe and has been submitted for U.S. regulatory approval. Drive efficiency and digitization to fuel growth and improve profitability: QIAGEN announced plans to achieve at least a 31% CER adjusted operating income margin in 2028. Key drivers involve a series of new initiatives to free up resources for reallocation and to expand operational margins. These initiatives include streamlining the portfolio, in particular the recent decision to discontinue the NeuMoDx system. They also include initiatives to simplify the organization, improve end-to-end processes, in particular through an upgrade of QIAGEN's SAP enterprise resource system; and optimize the site network. QIAGEN is seeking to harness the power of digitization to fuel growth and improve profitability, with about 30 AI initiatives under way. Ensure disciplined capital allocation for growth and shareholder value: QIAGEN plans to continue implementing its disciplined capital allocation strategy anchored by strong cash flow trends and a healthy balance sheet. This strategy involves profitable organic investments into the business; focused M&A through value-creating transactions, and a new plan to return at least $1 billion to shareholders from 2024 to 2028. QIAGEN returned approximately $300 million to shareholders through a synthetic share repurchase in January 2024, and shareholders will be asked at the upcoming Annual General Meeting to approve a new $300 million synthetic repurchase program. Deliver strategy through responsibility, empowerment and reinvigorated leadership: Achieving these 2028 targets can only be done by creating an even stronger culture among QIAGEN's 6,000 employees in terms of empowerment, accountability and ownership. QIAGEN reaffirmed its commitment to its ESG goals, including a validated target to reach net zero carbon emissions by 2050 and maximize contributions to more than 50 public health partnerships around the world.

07:35 EDT Amesite announces contract renewal with EWIE Group of Companies - Amesite is extending its partnership with EWIE Group of Companies. This is the third year that Amesite will deliver enterprise upskilling needs for EGC's global teams on EGC's proprietary Learning Community Environment.

07:34 EDT Redwire awarded DARPA contract for SabreSat Spacecraft VLEO demonstration - Redwire Corporation announced that it has been awarded a contract from the Defense Advanced Research Projects Agenc,y DARPA, to be the prime mission integrator for the development of a revolutionary air-breathing satellite that will demonstrate the use of novel electric propulsion systems in very low-Earth orbit, VLEO, using Redwire's SabreSat VLEO platform. The program leverages Redwire's worldwide leadership in developing and providing VLEO capabilities. The strategic significance of VLEO is growing - especially for national security missions. While low-Earth, LEO, and geosynchronous, GEO, orbits are becoming increasingly congested and contested, spacecraft in VLEO operate in a relatively unimpaired environment. Bridging the gap between air and space, VLEO spacecraft fly above airborne anti-access areas while operating significantly closer to the area of responsibility on the ground than existing satellites. Additionally, unlike LEO and GEO, debris in VLEO deorbits in hours or days rather than in decades or more. "We are proud to be leveraging our SabreSat satellite design to support critical VLEO technology advancements for DARPA's game-changing Otter program," said Spence Wise, Redwire Senior Vice President, Missions and Platforms. "As VLEO emerges as a critical domain for national security missions, Redwire is continuing to make investments to support technology innovation and strategic operations in this environment."

07:33 EDT Shake Shack appoints Stephanie Sentell as COO - Shake Shack announced that it has appointed Stephanie Sentell to the role of COO, effective July 1. Stephanie is a seasoned restaurant executive and most recently served as senior VP of company operations at Inspire Brands, where she oversaw the operations of more than 1,100 company-owned Arby's restaurants and led 22,000 restaurant team members across the United States. Stephanie has spent over 11 years at Inspire Brands and Arby's, most recently as SVP of company operations, managing a $1.5B business. As Shake Shack's new COO, Stephanie will oversee all company-operated domestic Shacks, including over 12,000 team members. She will report to Rob Lynch, Shake Shack's CEO and work closely with the current senior executive leadership team.

07:31 EDT Broadridge announces integration of its F&O SaaS Platform with TNS - Broadridge Financial Solutions announced the integration of its global Futures and Options, F&O, Software-as-a-Service, SaaS, Platform with Transaction Network Services, TNS, a global leader in providing mission-critical infrastructure for financial markets. TNS will enhance the functionality of Broadridge's F&O platform for the derivatives market by providing global exchange connectivity for order routing and market data access as the vendor of record. "With the addition of TNS, futures commission merchants and agency brokers will now have access to simplified, market data while benefiting from reduced implementation costs and improved time-to-market," said Mike Johnson, General Manager, F&O, Broadridge Trading and Connectivity Solutions. "Broadridge's F&O platform helps firms simplify and optimize trading through its modular and flexible deployment capabilities and we are committed to providing globally resilient solutions for our clients. This integration enhances our software offering and aligns with the growing industry trend where clients are moving away from hosting their own trading infrastructure."

07:30 EDT Aldebaran Resources reports results for drill holes at Altar Copper-Gold project - Aldebaran Resources reports results for three drill holes from the 2023/2024 field campaign at the Altar copper-gold project in San Juan, Argentina. All three holes intercepted significant mineralization and expanded the mineralized footprint, with ALD-24-243 intercepting one of the longest contiguous runs of mineralization encountered on the property to date. All three holes will provide valuable information for the upcoming mineral resource estimate, scheduled for H2 2024. Highlights: ALD-24-243: 1,517.00 m of 0.55% CuEq from 325.00 m depth; Including 919.55 m of 0.66% CuEq from 527.00 m depth; Including 227.00 m of 0.79% CuEq from 930.00 m depth; Extends the mineralized Altar United porphyry to the North, well beyond previous interpretations; Hole ended in mineralization. ALD-24-129EXT: 1,047.00 m of 0.38% CuEq from 164.00 m depth; Including 116.30 m of 0.56% CuEq from 713.00 m depth; Fills in a gap in the drilling for the upcoming mineral resource update; Hole ended in mineralization; Extension of historic hole that was originally terminated at 513.00 m depth. ALD-24-165EXT: 986.00 m of 0.29% CuEq; Including 333.50 m of 0.41% CuEq from 633.00 m depth; Including 109.10 m of 0.60% CuEq from 851.00 m depth; Fills in a gap in the drilling for the upcoming mineral resource update; Hole ended in mineralization; Extension of historic hole that was originally terminated at 484.50 m depth. John Black, CEO of Aldebaran, commented: "Intercepting more than 1.5 km of continuous attractive grade mineralization in ALD-243 is a testament to the size and scale of the Altar project. This project is already very large, but with each additional drill hole, we grow the mineralized footprint. Since our last resource estimate in 2021, we've completed more than 60,000 m of drilling on the project and we're very excited to see how much the overall mineral resource estimate will grow when we complete a resource update in H2 of this year."

07:22 EDT Microbix Biosystems hosts Minister Nina Tangri to open capacity extensions - Microbix Biosystems announces its hosting of Associate Minister of Small Business of Ontario, the Honourable Nina Tangri, to celebrate the opening of two expansions to its medical devices manufacturing capacity at one of its three adjacent Mississauga sites. Expansion one is a new 2,000 square foot laboratory to fulfill growing demand for Microbix's quality assessment products for diagnostic test-makers and other end-users, as well as for the internal quality control testing required to validate and release commercial production batches. The Lab may also be used for manufacturing swing capacity and for piloting automation processes. The Lab was entirely constructed from Ontario Made modular and prefab components. This innovative construction is more cost-effective than conventional framing and enables reconfiguration or relocation. Across its three sites, Microbix now has access to 11 distinct lab areas totaling 17,000 square feet, comprising 50% of its overall space. This Lab represents a capacity expansion of no less than 13% and the investment in this new capacity was C$ 0.6 million, being capitalized and amortized at 12.5% per year. Expansion two comprises a Made-In-Canada manufacturing line for fully-automated filling, capping, labeling, and bagging of vials of in-vitro diagnostics related reagents. The Line can be used to manufacture Microbix-branded patient-sample collection media and control elution buffers, as well as for custom white-label reagent production, with a targeted capacity of up to 3,000 vials per hour. The full cost of the Line and related renovations was C$ 1.2 million, also being capitalized and amortized. Tangri commented, "Microbix is a great example of a locally founded and led life sciences business creating innovative and clinically important products, manufacturing them here in Ontario, and exporting them around the globe. The Government of Ontario is pleased to support Microbix's mission to make next-generation diagnostic tests for infectious diseases more widely available and to help ensure their accuracy."

07:18 EDT Arvinas names Ian Taylor as Presdent, R&D, Angela Cacace as CSO - Arvinas announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chairperson, President and CEO. Dr. Taylor joined Arvinas in 2016 as Vice President of Pharmacology and Translational Medicine and has held positions of increasing responsibility, including serving as CSO of the company since early 2019. Dr. Cacace joined Arvinas in 2018 as Vice President of Neuroscience and Platform Biology, bringing over two decades of drug discovery experience in neuroscience and oncology research across modalities. She most recently served as Senior Vice President, Neuroscience and Platform Biology.

07:14 EDT Aeva Technologies selected by Digitale Schiene Deutschland for LiDAR - Aeva announced that the sector initiative Digitale Schiene Deutschland has selected Aeva's 4D LiDAR technology to support state-of-the-art perception and localization in the AutomatedTrain project. The Digitale Schiene Deutschland initiative is managed by DB InfraGO AG, part of Germany's national railway operator Deutsche Bahn.The AutomatedTrain project, funded by the German Federal Ministry of Economic Affairs and Climate Action with collaboration from ten partners, including Siemens Mobility and Bosch Engineering, aims to create and trial driverless, fully automated passenger train dispatch and parking functionality by 2026. To achieve this goal, two regional trains will be equipped with smart sensor technologies, including LiDAR, to enable the detection of their surroundings for full automation and reaction to obstacles, similar to how self-driving cars operate. "Aeva's high resolution LiDAR sensor combined with a compact form factor and advanced technology readiness level were in combination the reason for us to decide using Aeva for the AutomatedTrain project," said Dr. Christian Hauswald, Technical Project Lead of AutomatedTrain at Digitale Schiene Deutschland. "We are using the best available technologies and are excited to have Aeva as a supplier in this project because they share our vision for fully automated trains."

07:12 EDT AstraZeneca: IMFINZI +chemo gets approval for endometrial cancer with dMMR - AstraZeneca's IMFINZI or durvalumab in combination with carboplatin and paclitaxel followed by IMFINZI monotherapy has been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient or dMMR. The approval by the Food and Drug Administration, FDA was based on the results of a prespecified exploratory subgroup analysis by MMR status in the DUO-E Phase III trial. Results from DUO-E were published in the Journal of Clinical Oncology. ...Shannon N. Westin, Professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and principal investigator of the trial, said, "With the incidence and mortality of endometrial cancer expected to continue to increase significantly in the coming decades, it is more important than ever that we bring new treatment options to patients at the earliest possible moment in their care. This approval underlines clear evidence that durvalumab plus chemotherapy followed by durvalumab monotherapy delivers important clinical benefits for patients with mismatch repair deficient endometrial cancer."..The safety and tolerability profile of the IMFINZI and chemotherapy regimen was generally manageable, well tolerated and broadly consistent with prior clinical trials with no new safety signals...

07:10 EDT VersaBank appoints Campbell as Advisor to its board of directors - VersaBank announced it has appointed Glenn Campbell as Advisor to its Board of Directors. Campbell will be available to advise VersaBank's Board on a number of matters to ensure the Bank is well positioned for its proposed entry into the United States. Most recently, Campbell served more than seven years with Infrastructure Canada.

07:09 EDT BioRestorative Therapies regains compliance with Nasdaq listing rule - BioRestorative Therapies has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 with the Securities and Exchange Commission.

07:07 EDT Summit Midstream advances planned conversion to C-corporation - Summit Midstream Partners announced that it filed a proxy statement/prospectus and investor presentation and scheduled a Special Meeting of Common Unitholders to vote on the reorganization from a master limited partnership to a C-corporation. Heath Deneke, President, Chief Executive Officer, and Chairman, commented, "After carefully considering a wide range of opportunities, the Board is confident that reorganizing to a C-corporation is in the best interests of Summit and all unitholders. The transaction will reduce unitholders' tax burden; simplify Summit's structure to make the equity easier to own; enhance trading liquidity; greatly expand the universe of potential investors; and reduce administrative burden, providing greater transparency and easier decision-making for investors. We urge all Summit common unitholders to vote 'FOR' the reorganization to a C-corporation."

07:06 EDT Helius Medical completes participation enrollment for stroke program in the U.S. - Helius Medical Technologies announced the completion of site participation enrollment for its stroke registrational program in the U.S. with the addition of REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions. The stroke registrational program, which also includes Brooks Rehabilitation and Shepherd Center, is designed to establish the effects of cranial-nerve non-invasive neuromodulation, delivered using PoNS Therapy, on gait and dynamic balance in chronic stroke survivors. Under the direction of Avrielle Rykman Peltz, M.A., OTR/L and Dr. Jay Lombard, D.O., REHABOLOGYM has already enrolled six subjects and expects to reach at least ten patients by early July. NCNE and MGH-IHP joined the study in May and June, respectively, and both sites will begin enrollment in July. Brooks Rehabilitation started enrollment in April with three participants to date while Shepherd Center enrolled two participants in May and expects to add two more by the end of June. Helius anticipates enrolling at least thirty patients into the open label study, across all sites, by the end of the third quarter.

07:05 EDT Polestar to expand commercial footprint through new sales model - Polestar is expanding its commercial footprint and retail operations across existing and new markets, as its model line-up continues to grow. The company is widening its retail footprint with existing and new partners, as part of a shift to a non-genuine agency sales model across Europe. Customers will still be able to configure and order their Polestar online, as well as through the expanding network of Polestar Spaces and service locations. Sweden and Norway switched to a non-genuine agency sales model earlier this month with other key markets set to follow suit in the second half of the year. Polestar is accelerating its geographic expansion and plans to enter seven new markets during 2025. France is the largest volume market for electric cars in the EU after Germany and represents a significant opportunity for the company. In addition, Polestar will look to launch in Czech Republic, Slovakia, Hungary, Poland, Thailand and Brazil via local distribution partnerships.

07:04 EDT Energy Fuels appoints Bennethum to Energy Fuels' Management Team as Director - Energy Fuels (UUUU) appoints Debra Bennethum to Energy Fuels' Management Team as Director, Critical Minerals & Strategic Supply Chain. Bennethum is a chemical engineer who previously served as the EV Critical Minerals Manager in the Global Purchasing and Supply Chain Division of General Motors (GM).

07:03 EDT Toyota, Pepco team up to research vehicle-to-grid technology - Toyota Motor North America and local energy utility Pepco are working together on vehicle-to-grid, V2G, research for battery electric vehicles, BEVs, using a Toyota bZ4X. This collaborative effort will explore bidirectional power flow technology that will allow BEV owners to not only charge their vehicle's battery but also send power back to the local energy grid. "Bidirectional charging is a great way for customers to leverage their electric vehicles in a way that supports the grids and their home electricity ecosystem," said Christopher Yang, group vice president, Toyota EV Charging Solutions. "Working with Pepco will help us understand charging and discharging use-cases, which will ultimately benefit our customers and help utility providers better understand grid demands."

07:01 EDT Altair One cloud innovation gateway available on Google Cloud - Altair (ALTR) announced that Altair One, Altair's cloud innovation gateway, is now available on Google Cloud (GOOGL) Marketplace, "opening up a world of possibilities for users seeking seamless access to powerful simulation, data analytics, and high-performance computing capabilities," the company said.

07:00 EDT Vapotherm to be acquired by Perceptive Advisors for $2.18 per share - Vapotherm announced that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, a health care investment firm and its Perceptive Discovery Fund. Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50M of new preferred equity capital into the business, a portion of which will be used to fund the merger consideration and make certain closing-related payments. SLR will retain $40M of term debt. Under the terms of the definitive merger agreement, Vapotherm's stockholders will receive $2.18 in cash for each outstanding share of company common stock held immediately prior to the effective time of the merger, other than shares held by certain Vapotherm stockholders who have agreed to contribute their shares of company common stock in exchange for ownership interests in the newly-formed entity. The merger consideration of $2.18 per share represents a premium of approximately 166% over the closing price of Vapotherm common stock on June 14, the last trading day prior to public disclosure of the transaction. A special committee of the board of directors of Vapotherm, comprised solely of independent directors and advised by its own independent financial advisor, unanimously recommended that the board approve the merger agreement and the transaction and determined it was in the best interests of Vapotherm and its stockholders. Acting upon the recommendation of the special committee, the board approved the merger agreement and the transaction and has recommended that the company's stockholders approve the adoption of the merger agreement and approve the transaction on the terms set forth in the merger agreement. The transaction is expected to close in the second half of 2024 and is subject to customary closing conditions, including receipt of stockholder approval. Upon completion of the transaction, Vapotherm will become a private company and will no longer be publicly listed or traded on OTCQX.

06:58 EDT Ovid Therapeutics notes Takeda's announcement on Phase 3 results of soticlestat - Ovid Therapeutics Inc. (OVID) reports that Takeda Pharmaceutical Company Limited (TAK) has announced topline data from its Phase 3 SKYLINE and SKYWAY studies evaluating soticlestat for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. Jeremy Levin, D. Phil, MB Chir, Chairman and CEO of Ovid, stated, "We are surprised and disappointed with the primary endpoint results. Soticlestat has a unique mechanism of action and a favorable tolerability profile, though its potential was not elucidated in SKYWAY. While SKYLINE narrowly missed its primary endpoint, we believe there are indications of effect in the secondary endpoints and the totality of the data in DS patients. Takeda is thoughtfully evaluating that data to inform the path forward with regulatory authorities." SKYLINE was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat plus standard of care as compared to placebo plus standard of care in patients with refractory DS. Soticlestat narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency as compared to placebo. Among the six key secondary endpoints, soticlestat showed clinically meaningful and significant results in the responder rate, measures of caregiver and clinician global impression of improvement, and seizure intensity and duration scales over the 16-week treatment period. In the Phase 2 study, ELEKTRA, soticlestat demonstrated a statistically significant reduction of seizures from baseline compared to placebo in the combined DS and LGS study population during the full treatment period. In the DS cohort, statistically significant reduction in convulsive seizure frequency from baseline compared to placebo was also achieved. In a pooled analysis of SKYLINE and the DS cohort of the Phase 2 ELEKTRA study, soticlestat also showed a reduction from baseline in convulsive seizure frequency compared to placebo. SKYWAY was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat plus the standard of care as compared to placebo plus the standard of care in patients with refractory LGS. Soticlestat missed the primary endpoint of reduction from baseline in major motor drop seizure frequency as compared to placebo. In SKYLINE and SKYWAY, some pre-specified subgroups of patients showed significant treatment effects on the primary endpoint and on secondary efficacy endpoints of caregiver global impression of improvement, clinician global impression of improvement, and seizure intensity and duration scales over the 16-week treatment period. Further analyses are being conducted. Soticlestat was generally well tolerated in both the SKYLINE and the SKYWAY studies and demonstrated a safety profile consistent with the findings of previous studies. Soticlestat is a novel mechanism of action and has no known clinically meaningful drug-to-drug interactions with anti-seizure medications. Takeda plans to engage with regulatory authorities to discuss the totality of the data generated by the soticlestat studies to determine next steps. Takeda will also plan to present results of both Phase 3 studies at an upcoming scientific congress.

06:50 EDT Takeda says SKYLINE, SKYWAY studies of soticlestat miss primary endpoints - Takeda announced topline data from its SKYLINE and SKYWAY studies. SKYLINE was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat plus standard of care versus placebo plus standard of care in patients with refractory Dravet syndrome. Soticlestat narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency as compared to placebo. Among the six key secondary endpoints, soticlestat showed clinically meaningful and nominally significant results in the responder rate, measures of caregiver and clinician global impression of improvement, and seizure intensity and duration scales over the 16-week treatment period. SKYWAY was a multicenter, randomized, double-blind Phase 3 study that evaluated soticlestat plus standard of care versus placebo plus standard of care in patients with refractory Lennox-Gastaut syndrome. Soticlestat missed the novel primary endpoint of reduction from baseline in Major Motor Drop seizure frequency as compared to placebo. In SKYLINE and SKYWAY, some pre-specified subgroups of patients also showed nominally significant treatment effects on the primary and secondary efficacy endpoints of caregiver and clinician global impression of improvement, and seizure intensity and duration scales over the 16-week treatment period. Further analyses are being conducted. Soticlestat was generally well tolerated in both SKYLINE and SKYWAY studies and demonstrated a safety profile consistent with the findings of previous studies. In the Phase 2 study, ELEKTRA, soticlestat demonstrated a statistically significant reduction of seizures from baseline compared to placebo in the combined DS and LGS study population during the full treatment period.3 In the DS cohort, statistically significant reduction in convulsive seizure frequency from baseline compared to placebo was also achieved.3 In a pooled analysis of SKYLINE and the DS cohort of the Phase 2 ELEKTRA study, soticlestat also showed a reduction from baseline in convulsive seizure frequency compared to placebo. Takeda will engage with regulatory authorities to discuss the totality of the data generated by these studies to determine next steps. Takeda will also plan to present results of both Phase 3 studies at an upcoming scientific congress. Takeda is continuing to assess the financial impacts of the study results, including impairment loss for intangible assets, on the first quarter ending June 30, 2024 and will communicate as necessary in due course.

06:33 EDT iHeartMedia, Deep Blue Sports + Entertainment announce lineup of WSAN shows - iHeartMedia and Deep Blue Sports + Entertainment announced the inaugural lineup of original podcast shows for WSAN, the first-ever audio platform dedicated exclusively to women's sports - from soccer and basketball to tennis, golf, volleyball and more - featuring top athletes and personalities at the helm. Additionally, Capital One, e.l.f Cosmetics and e.l.f SKIN join as the founding partners of the new network. As a free, ad-supported network available across iHeartMedia's broadcast, digital and podcast platforms and everywhere podcasts are heard, the Women's Sports Audio Network is designed to amplify well-known and new influential women sports athletes and relevant programming to millions of listeners nationwide, and also unlock access to inventory and opportunities for brands to engage. Along with a slate of new shows, on June 18 WSAN will launch regular "Women's Sports Reports" across iHeartMedia's industry-leading broadcast radio stations nationwide, marking a landmark moment in bringing more equitable media coverage to women's sports for the first time. At a time when the demand and interest in women's sports have never been higher, iHeartMedia's commitment to women's sports will level the playing field in coverage, as iHeart is uniquely prepared to maximize exposure nationwide. iHeartMedia will flip the switch for the "Women's Sports Reports" live at the Cannes Lions Festival in France, where Deep Blue Sports + Entertainment will host the Women's Sports House, in partnership with Axios. The Women's Sports House is part of TN50, a dedicated content platform and thought leadership series from Axios and Deep Blue Sports + Entertainment that explores the dollars and decisions required to drive "The Next 50" years in women's sports. The event includes three days of dedicated programming exploring the future of business, leadership, creativity and talent within women's sports for the next 50 years.

06:13 EDT Primo Water, BlueTriton Brands merge in all-stock transaction - Primo Water and an affiliate of BlueTriton Brands announced the entry into a definitive agreement to create a North American pure-play hydration company in an all-stock transaction that was unanimously approved by their respective boards of directors. Upon closing of the transaction, Primo Water shareholders and holders of incentive equity are expected to own 43% of the fully diluted shares of the combined company, and BlueTriton shareholders are expected to own 57% of the fully diluted shares of NewCo. The combined company will have significant financial and operating presence with combined net revenue and adjusted EBITDA, inclusive of $200M in estimated cost synergies, of $6.5B and $1.5B, respectively, for the twelve month period ended March 31. Since the acquisition, BlueTriton's net revenue grew from $3.9B in 2021 to $4.7B during the twelve-month period ended March 31, a compounded annual growth rate of 9%. Adjusted EBITDA grew from $531M to $857M over that same period, a compounded annual growth rate of 24%. The transaction will bring together Primo Water and BlueTriton's strengths, including $200M in estimated cost synergies of $6.5B and $1.5B, respectively, for the twelve month period ended March 31. One-time costs associated in the capture of the $200M synergies opportunity are estimated to be approximately $115M. The transaction is expected to present an estimated run-rate cost synergies opportunity of approximately $200M, which the companies estimate will be fully realized within three years following the closing of the transaction. The combined company generated over $565M in combined adjusted free cash flow for the twelve month period ended March 31 and is targeting combined normalized capital expenditures as a percent of net revenue to be approximately 4%-5% going forward. The transaction was structured to allow NewCo to keep both Primo Water and BlueTriton's bonds and term loans in place, if the parties desire to do so. At closing, combined net leverage is expected to be approximately 3.0x, inclusive of estimated run-rate cost synergies, assuming that closing occurs during the first half of 2025 and that the existing indebtedness of Primo Water and BlueTriton remain outstanding. The combined company is targeting deleveraging to Net Debt/Adjusted EBITDA of 2.0x - 2.5x in the medium-term following the closing of the transaction. NewCo currently anticipates maintaining Primo Water's current annualized dividend of 36c per share. The long-term dividend policy of the combined company will be determined and communicated post-closing. Under the terms of the agreement, Primo Water and BlueTriton shareholders will exchange their respective shares into shares of a new holding company. Upon closing of the transaction, Primo Water shareholders and holders of incentive equity are expected to own 43% of the fully diluted shares of NewCo, and BlueTriton shareholders are expected to own 57% of the fully diluted shares of NewCo; the portion of shares of NewCo in excess of 49% that are held by any individual or group of former BlueTriton shareholders would be in the form of a separate class of common stock that is non-voting as to the election of directors of NewCo. The combined company is expected to continue to be listed on the NYSE, subject to approval of such listing by the NYSE. Upon closing of the transaction, the common shares of Primo Water, as a wholly owned subsidiary of NewCo, will no longer be listed on any public market. Under the terms of the definitive agreement, the transaction will be effected by way of a court-approved plan of arrangement involving Primo Water under the Business Corporations Act and a merger involving BlueTriton under the laws of Delaware. The transaction is subject to approval by Primo Water's shareholders, as well as the satisfaction of customary closing conditions, including expiration of the waiting period under the HSR Act, receipt of other regulatory approvals and court approval of the arrangement of Primo Water. The transaction is expected to close in the first half of 2025. The directors and executive officers of Primo Water, holding an aggregate of approximately 2.1% of the outstanding common shares of Primo Water, have each entered into support and voting agreements to vote their shares in favor of the arrangement of Primo Water. The definitive agreement permits Primo Water to continue to pay its regular quarterly dividend to shareholders and to pay a special dividend to its shareholders in an aggregate amount of up to $133M, or 82c per share. Primo Water intends to pay the special dividend following board approval and setting of the record date and payment date prior to closing of the transaction. The combined company is expected to initially have a 15-person board of directors, seven members of which will be initially appointed by Primo Water, seven members of which will be initially appointed by BlueTriton and one member of which will be mutually agreed.

06:11 EDT Shoals Technologies to launch global suite of solutions at Intersolar Europe - Shoals Technologies Group announced its launch of a comprehensive range of system-solutions focused on international developers and engineering, procurement and construction contractors. The new product launch will take place at Intersolar Europe, June 19-21 and will introduce the most comprehensive suite of solutions by Shoals to-date, specifically designed with global customers in mind. The rollout will include solutions that enable unobstructed rows, agri-solar, as well as North-South configurations in addition to existing East-West configuration solutions. In developing this new line of solutions, Shoals has listened to customers and market feedback, and recognized that the world of utility scale solar is evolving. The innovation team has delivered plug-and-play, industrialized product solutions to meet the needs of today and the future. Shoals products are prefabricated and negate the need for insulation piercing connectors that do not meet developers' strict quality standards needed to withstand the time and extreme weather experienced in large scale systems. In addition to globally certified versions of existing products which Shoals offers in the US, the new innovations include: SuperJumper - a prefabricated home-run solution. Trenched BLA - for applications where a messenger wire is an obstacle. Mini BLA - for smaller installations or where topography dictates a segmented configuration of trackers. Smart Combiner - boxes that integrate seamlessly with SCADA systems.

06:08 EDT Gilat Satellite to acquire Stellar Blu for initial cash payment of $98M - Gilat Satellite Networks has signed a definitive agreement to acquire Stellar Blu Solutions LLC, which will become a core component of Gilat's IFC growth strategy. Stellar Blu Solutions is a US-based leading avionics solution provider of next-generation SATCOM terminal solutions. The acquisition is a significant step in Gilat's initiative to increase its presence in the growing IFC market. Gilat expects its annual revenues from the acquired business to range between $100 Million to $150 Million beginning in 2025, based on Stellar Blu's existing backlog. The acquisition is expected to be accretive on a non GAAP basis starting the second half of 2025. Gilat will pay an initial cash payment of $98 Million at closing, subject to customary adjustments, and up to an additional $147 Million payable in cash, subject to the achievement of post-closing financial and business goals. Gilat intends to finance the acquisition with its existing cash reserves and an external credit facility. The transaction has been approved by Gilat's Board of Directors and by Stellar Blu Solutions Board of Managers. The closing of the transaction is subject to certain regulatory approvals, including the receipt of clearance from the Committee on Foreign Investment in the United States and the U.S. Federal Trade Commission and the Department of Justice under the HSR Act, as well as other customary closing conditions. The acquisition is expected to close in the second half of 2024. Stellar Blu Solutions specializes in the development of specialized connectivity, network, and electronics solutions for satellite networks. The Stellar Blu "Sidewinder" solution is novel in its open architecture, full ESA terminal optimized to enable the performance and cost advantages of multi-orbit strategies. The Sidewinder architecture is modular and easily extensible into other aerospace, and mobility applications. The Stellar Blu platform has been selected by Intelsat, Panasonic, OneWeb and others, to provide next-generation satcom solution offerings. Through this network of partners, the Stellar Blu solution has been embraced by some of the world's largest airlines.

06:04 EDT Keros Therapeutics presents clinical data from elritercept program - Keros Therapeutics presented additional data from its two ongoing Phase 2 clinical trials of elritercept, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes and one in patients with myelofibrosis, at the 29th Annual Hybrid Congress of the European Hematology Association, held in person in Madrid, Spain and virtually from June 13 through 16, 2024. In addition, Keros presented preclinical data showing that, in an animal model of MF, a research form of elritercept promoted erythropoiesis, mitigated anemia associated with MF, improved anemia associated with ruxolitinib therapy and improved muscle mass and function. Durable Clinical Benefit with Elritercept Treatment: Findings From an Ongoing Phase 2 Trial in Participants with Lower-Risk MDS: This ongoing, open-label, two-part, Phase 2 clinical trial is evaluating elritercept in patients with very low-, low-, or intermediate-risk MDS. As of April 3, 2024, 87 patients had received at least one dose of elritercept at the recommended Part 2 dose. Of these patients in the safety population, 81 had completed at least 24 weeks of treatment or discontinued as of the data cut-off date. Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients. All data presented from this trial is as of the data cut-off date. Of the 87 patients in the safety population, 57.5% were high transfusion burden while 25.3% were low transfusion burden and 17.2% were non-transfused. Elritercept was observed to be generally well-tolerated in the safety population. There were three cases of fatal treatment-emergent adverse events in the trial that were all deemed unrelated to treatment. The most commonly reported TEAEs were diarrhea, fatigue, dyspnea, dizziness, COVID-19, nausea and anemia. No patients had progressed to acute myeloid leukemia. 55.6% of the mITT24 patients achieved an overall erythroid response over the first 24 weeks of treatment, which is defined as meeting either modified International Working Group 2006 Hematological improvement-erythroid or transfusion independence for at least eight weeks in transfusion-dependent patients who required greater than or equal to 2 red blood cell units transfused at baseline. Additional data from the mITT24 patients include: 41.3% of the TI-evaluable patients achieved TI for at least eight weeks over the first 24 weeks of treatment. 16 of those 26 patients achieved TI for at least 24 weeks over the first 48 weeks of treatment. Of the patients with HTB, 34.8% achieved TI for at least eight weeks during the first 24 weeks of treatment. Eight of those 16 patients achieved TI for at least 24 weeks over the first 48 weeks of treatment. Of the TI-evaluable patients with baseline erythropoietin level less than 500 U/L, 50.0% achieved TI for at least eight weeks over the first 24 weeks of treatment. Of the TI-evaluable patients with baseline erythropoietin level less than 500 U/L and HTB, 42.9% achieved TI for at least eight weeks over the first 24 weeks of treatment. The median duration of transfusion independence was not met as of the data-cutoff date. 61.5% of patients with a TI response had ongoing TI as of the data-cutoff. Of the patients that achieved TI, 42.3% had responses of greater than one year, with all ongoing as of the data cut-off date. The FACIT-Fatigue scale, a measure of self-reported fatigue and its impact upon daily activities and function, was utilized to assess health-related quality of life in 62 of the mITT24 patients who were TI-evaluable and with baseline FACIT-Fatigue assessment. A difference of three in the FACIT-Fatigue scale is considered a minimally clinically important difference. In this group, patients who achieved TI had durable and clinically meaningful improvements in self-reported fatigue. Patients achieving TI of 24 weeks or longer had a mean change from baseline of 6.6 versus patients who did not achieve TI of at least 24 weeks, who reported a mean change from baseline of -2.7, for a mean difference of 9.4. The majority of patients enrolled in this ongoing trial had HTB and/or multi-lineage dysplasia, indicating a difficult-to-treat trial population. Durable TI responses continue to be observed in a broad range of patients with lower-risk MDS, including in those with HTB, which support the potential for elritercept to ameliorate ineffective hematopoiesis across multiple lineages in patients with MDS. Patients who achieved TI showed clinically meaningful improvements in FACIT-Fatigue scores, indicating that elritercept may improve quality of life in patients with lower-risk MDS.

05:19 EDT Nasdaq, Indonesia Stock Exchange expand technology partnership - Nasdaq and the Indonesia Stock Exchange announced an expansion of their technology partnership which will see IDX upgrade its core trading platform to Nasdaq's most advanced matching engine. The deal also includes an extension of Nasdaq's market surveillance partnership with IDX, and an agreement to enhance IDX's Index business to help foster a deeper and sophisticated global capital markets ecosystem. In addition to Nasdaq's long-standing relationship with IDX, Nasdaq provides market surveillance technology to OJK, Indonesia's Financial Services Authority, the core technology platform that underpins KSEI, Indonesia's central securities depository, and its Calypso treasury solution to Bank Indonesia, the country's central bank.

05:13 EDT ING Groep provides three-year financial targets ahead of capital markets day - ING is hosting a Capital Markets Day. Steven van Rijswijk, CEO of ING, and the other members of ING's management board will provide an update on the next phase of ING's strategy. As part of the Capital Markets Day, the company will share financial targets for the period 2024-2027. The company said, "In this period, we aim to grow our number of mobile primary customers by one million per annum and target an annual total income growth of 4-5%. For 2027, we target a fee income of EUR 5 billion, a cost/income ratio of 52-54% and a return on equity of 14%. Our CET1 ratio target of around 12.5% by end of 2025 is reaffirmed and will be periodically reviewed against capital requirements. Building on our strategic pillars of superior value for customers and putting sustainability at the heart, we present our plan to increase impact, build scale in more market segments and play a bigger role in the economies we operate in. We will invest to expand our product offerings, grow our customer base, and deepen our customer relationships. We increase capital allocation to our retail business while focusing on growth combined with improving capital efficiency in wholesale banking. We also provide an update today on our ambition to be a leader in financing the sustainable transition. We continue to manage our portfolio towards net-zero by 2050, taking a science-based approach per sector. As announced earlier, we will phase out financing of oil and gas production by 2040 while aiming to triple the financing of renewable energy to EUR 7.5 billion annually by 2025. We update our target for sustainable volume mobilised to EUR 150 billion per annum by 2027."

05:08 EDT Instacart extends first-party retail media data to YouTube - Instacart (CART) announced that it is extending its first-party retail media data to YouTube (GOOG), driving even more shoppable reach for its advertisers. Select brand partners will be able to inspire and convert consumers watching YouTube directly to purchase for same-day delivery. The new capability builds on Instacart's Instacart-powered Google Shopping Ads collaboration announced earlier this year.